How to buy Arrowhead Pharmaceuticals stock (ARWR)

Arrowhead Pharmaceuticals is a biotechnology business based in the US. Arrowhead Pharmaceuticals shares (ARWR) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $18.96 – a decrease of 2.52% over the previous week. Arrowhead Pharmaceuticals employs 525 staff and has a trailing 12-month revenue of around $19.6 million.

Our top picks for where to buy Arrowhead Pharmaceuticals stock

Buy Arrowhead Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Arrowhead Pharmaceuticals stock price (NASDAQ: ARWR)

Use our graph to track the performance of ARWR stocks over time.

Arrowhead Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$18.96
52-week range	$17.05 - $39.83
50-day moving average more info button	$21.13
200-day moving average more info button	$23.59
Wall St. target price	$47.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.00

Is it a good time to buy Arrowhead Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arrowhead Pharmaceuticals price performance over time

Historical closes compared with the close of $19.53 from 2024-12-26

1 week (2024-12-20)	0.41%
1 month (2024-11-27)	-25.32%
3 months (2024-09-27)	-0.71%
6 months (2024-06-27)	-23.98%

1 year (2023-12-27)	-37.06%
2 years (2022-12-27)	-48.77%
3 years (2021-12-27)	66.3
5 years (2019-12-27)	64.93

Arrowhead Pharmaceuticals financials

Revenue TTM	$19.6 million
Gross profit TTM	$240.7 million
Return on assets TTM	-40.72%
Return on equity TTM	-151.84%
Profit margin	0%
Book value	$2.66
Market Capitalization more info button	$2.4 billion

TTM: trailing 12 months

Arrowhead Pharmaceuticals share dividends

We're not expecting Arrowhead Pharmaceuticals to pay a dividend over the next 12 months.

Have Arrowhead Pharmaceuticals's shares ever split?

Arrowhead Pharmaceuticals's shares were split on a 1:10 basis on 16 November 2011 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arrowhead Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arrowhead Pharmaceuticals shares which in turn could have impacted Arrowhead Pharmaceuticals's share price.

Arrowhead Pharmaceuticals share price volatility

Over the last 12 months, Arrowhead Pharmaceuticals's shares have ranged in value from as little as $17.05 up to $39.83. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arrowhead Pharmaceuticals's is 0.934. This would suggest that Arrowhead Pharmaceuticals's shares are less volatile than average (for this exchange).

Arrowhead Pharmaceuticals overview

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.

Frequently asked questions

null
What percentage of Arrowhead Pharmaceuticals is owned by insiders or institutions?
Currently 4.466% of Arrowhead Pharmaceuticals shares are held by insiders and 79.707% by institutions. How many people work for Arrowhead Pharmaceuticals?
Latest data suggests 525 work at Arrowhead Pharmaceuticals. When does the fiscal year end for Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals's fiscal year ends in September. Where is Arrowhead Pharmaceuticals based?
Arrowhead Pharmaceuticals's address is: 177 East Colorado Boulevard, Pasadena, CA, United States, 91105 What is Arrowhead Pharmaceuticals's ISIN number?
Arrowhead Pharmaceuticals's international securities identification number is: US04280A1007 What is Arrowhead Pharmaceuticals's CUSIP number?
Arrowhead Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 042797100